


# Bölüm 22

## Pankreas Başı Tümörlerinde Cerrahi Tedavi



Direnç YİĞİT<sup>1</sup>

### Giriş

Pankreas kanseri, dünyada yıllık ortalama 250 bin kişiyi etkilemektedir ve kanser ile ilişkili ölümlerin en önemli nedenlerindenidir (1). Cerrahi, uzun dönem sağ kalımda en önemli şansı sağlamaktadır; ancak hastaların yalnızca küçük bir bölümü (%10-20), hastalık tanısı aldığında küratif rezeksiyon için uygun bulunmaktadır (2).

Pankreas başı tümörlerinde uygulanan pankreatikoduodenektomi kompleks ve yüksek riskli bir prosedürdür. En iyi sonuçlar yüksek volümlü merkezlerde sağlanmaktadır (3,4). Deneyimli ellerde prosedür için ortalama operasyon süresi 5,5 saat, ortalama kan kaybı 350 ml ve mortalite %4'ten azdır (5). Pankreas başı rezeksiyonu gerektiren endikasyonlar Tablo 1'de belirtilmiştir.

**Tablo 1. Pankreas başı rezeksiyonu için endikasyonlar**

Pankreatik adenokarsinom
Ampuller karsinom
Ampuller adenom
Nöroendokrin tümörler
Kolanjiokarsinom
Duodenal neoplazm
Cerrahi müdahale endikasyonu olan kombiné pankreatik/duodenal yaralanmalar
Kronik pankreatit

<sup>1</sup> Uzm. Dr., Bursa Şehir Hastanesi Gastroenteroloji Cerrahisi Kliniği, direncyigit@gmail.com

## KAYNAKLAR

1. Yeo TP, Lowenfels AB. Demographics and epidemiology of pancreatic cancer. *Cancer J.* 2012;18(6):477-84.
2. Krempien R, Muentier M, Harms W, et al., Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. *HPB (Oxford).* 2006;8(1):22-8.
3. Birkmeyer JD, Sun Y, Wong SL, et al. Hospital volume and late survival after cancer surgery. *Ann Surg* 2007; 245:777.
4. Fong Y, Gonan M, Rubin D, et al. Long-term survival is superior after resection for cancer in high-volume centers. *Ann Surg* 2005; 242:540.
5. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. *Ann Surg* 2006; 244:10.
6. Braga M, Ljungqvist O, Soeters P, et al. ESPEN Guidelines on Parenteral Nutrition: surgery. *Clin Nutr* 2009; 28:378.
7. Mizuguchi K, Ajiki T, Onoyama T, et al. Short-term effects of external and internal biliary drainage on liver and cellular immunity in experimental obstructive jaundice. *J Hepatobiliary Pancreat Surg.* 2004; 11:176-80
8. Eshuis WJ, van Der Gaag NA, Rauws EA, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. *Ann Surg.* 2010; 252:840-9.
9. Huang X, Liang B, Zhao XQ, et al. The effects of different preoperative biliary drainage methods on complications following pancreaticoduodenectomy. *Medicine (Baltimore).* 2015;94: e723.
10. Gloor B, Todd KE, Reber HA. Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach. *Cancer* 1997; 79:1780.
11. Steinberg WM, Barkin J, Bradley EL 3rd, et al. Workup of a patient with a mass in the head of the pancreas. *Pancreas* 1998; 17:24.
12. Taoka H, Hauptmann E, Traverso LW, et al. How accurate is helical computed tomography for clinical staging of pancreatic cancer? *Am J Surg* 1999; 177:428.
13. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. *AJR Am J Roentgenol* 1997; 168:1439.
14. Vedantham S, Lu DS, Reber HA, et al. Small peripancreatic veins: improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT. *AJR Am J Roentgenol* 1998; 170:377.
15. American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. *Gastroenterology* 1999; 117:1463.
16. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. *Ann Surg Oncol* 2009; 16:1727.
17. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. *Radiology* 2014 Jan; 270(1):248-260

18. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2021 Apr 1;19(4):439-457.
19. Diepenhorst GM, van Ruler O, Besselink MG, et al. Influence of prophylactic probiotics and selective decontamination on bacterial translocation in patients undergoing pancreatic surgery: a randomized controlled trial. *Shock* 2011; 35:9.
20. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. *Arch Intern Med* 2006; 166:458.
21. Reinke CE, Drebin JA, Kreider S, et al. Timing of preoperative pharmacoprophylaxis for pancreatic surgery patients: a venous thromboembolism reduction initiative. *Ann Surg Oncol* 2012; 19:19.
22. Gemenetzis G, Groot VP, Blair AB, et al. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. *J Surg Oncol* 2018; 118:1277.
23. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. *Arch Surg* 2007; 142:767.
24. Staerkle RF, Vuille-Dit-Bille RN, Soll C, et al. Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. *Cochrane Database Syst Rev* 2021; 1:CD011490.
25. Redely SK, Tyler DS, Pappas TN, et al. Extended resection for pancreatic adenocarcinoma. *Oncologist* 2007; 12; 654-63.
26. Pedrazzoli S, Di Cairo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. *Lymphadenectomy study group. Ann Surg* 1998; 228:508-17
27. Evans DB, Farnell MB, Lillemoe KD, et al. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. *Ann Surg Oncol* 2009; 16:1736.
28. Hartel M, Neidergethmann M, Farag-Soliman M, et al. Benefit of venous resection for ductal adenocarcinoma of pancreatic head. *Eur J Surg.* 2002; 168; 707-12.
29. Shimada K, Sano T, Sakamoto Y, et al. Clinical implications of combined porta vein resection as palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. *Ann Surg Oncol* 2006; 156; 9-78.
30. Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. *Br J Surg* 2005; 92:547.
31. Lin PW, Shan YS, Lin YJ, et al. Pancreaticoduodenectomy for pancreatic head cancer: PPPD versus Whipple procedure. *Hepatogastroenterology* 2005; 52:1601.
32. Wenger FA, Jacobi CA, Haubold K, et al. [Gastrointestinal quality of life after duodenopancreatectomy in pancreatic carcinoma. Preliminary results of a prospective randomized study: panreatoduodenectomy or pylorus-preserving panreatoduodenectomy]. *Chirurg* 1999; 70:1454.
33. Tran KT, Smeenk HG, van Eijck CH, et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. *Ann Surg* 2004; 240:738.

34. Bloechle C, Broering DC, Latuske C, et al. Prospective randomized study to evaluate quality of life after partial pancreateoduodenectomy according to Whipple versus pylorus preserving pancreateoduodenectomy according to Longmire-Traverso for periampullary carcinoma. *Dtsch Gesellschaft Chir* 1999; Suppl-1:661.
35. Paquet KJ. Vergleich der partiellen Duodenopankreatektomie (Whipple operation) mit der pylorouserhaltenden Zephaloduodenopankreatektomie: eine prospektive kontrollierte, randomisierte Langzeitstudie. *Chir Gastroenterol* 1998; 14:54.
36. Hackert T, Probst P, Knebel P, et al. Pylorus Resection Does Not Reduce Delayed Gastric Emptying After Partial Pancreateoduodenectomy: A Blinded Randomized Controlled Trial (PROPP Study, DRKS00004191). *Ann Surg* 2018; 267:1021.
37. Klaiber U, Probst P, Hüttner FJ, et al. Randomized Trial of Pylorus-Preserving vs. Pylorus-Resecting Pancreateoduodenectomy: Long-Term Morbidity and Quality of Life. *J Gastrointest Surg* 2020; 24:341.
38. Hüttner FJ, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. *Cochrane Database Syst Rev* 2016; 2:CD006053.
39. Bassi C, Falconi M, Molinari E, et al. Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study. *Ann Surg* 2005; 242:767. U 74
40. Yeo CJ, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. *Ann Surg* 1995; 222:580.
41. Wellner UF, Sick O, Olschewski M, et al. Randomized controlled single-center trial comparing pancreaticogastrostomy versus pancreaticojejunostomy after partial pancreateoduodenectomy. *J Gastrointest Surg* 2012; 16:1686.
42. Duffas JP, Suc B, Msika S, et al. A controlled randomized multicenter trial of pancreaticogastrostomy or pancreaticojejunostomy after pancreateoduodenectomy. *Am J Surg* 2005; 189:720.
43. Rault A, SaCunha A, Klopfenstein D, et al. Pancreaticojejunal anastomosis is preferable to pancreaticogastrostomy after pancreaticoduodenectomy for longterm outcomes of pancreatic exocrine function. *J Am Coll Surg* 2005; 201:239.
44. Keck T, Wellner UF, Bahra M, et al. Pancreatogastrostomy Versus Pancreatojejunostomy for REConstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial. *Ann Surg* 2016; 263:440.
45. Topal B, Fieuws S, Aerts R, et al. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. *Lancet Oncol* 2013; 14:655.
46. Takano S, Ito Y, Watanabe Y, et al. Pancreaticojejunostomy versus pancreaticogastrostomy in reconstruction following pancreaticoduodenectomy. *Br J Surg* 2000; 87:423.
47. Cheng Y, Briarava M, Lai M, et al. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy. *Cochrane Database Syst Rev* 2017; 9:CD012257.

48. Kilambi R, Singh AN. Duct-to-mucosa versus dunking techniques of pancreaticojejunostomy after pancreaticoduodenectomy: Do we need more trials? A systematic review and meta-analysis with trial sequential analysis. *J Surg Oncol* 2018; 117:928.
49. Shrikhande SV, Kleeff J, Büchler MW, et al.(2007) Pancreatic anastomosis after pancreaticoduodenectomy: How we do it. *Indian Journal of Surgery* 69(6):224–229.
50. Kleespies A, Rentsch M, Seeliger H, et al. (2009) Blumgart anastomosis for pancreaticojejunostomy minimizes severe complications after pancreatic head resection. *Br J Surg* 96(7):741–750.
51. Wang SE, Shyr BU, Chen SC, et al. (2018) Comparison between robotic and open pancreaticoduodenectomy with modified Blumgart pancreaticojejunostomy: A propensity score–matched study. *Surg (United States)* 164(6):1162–1167.
52. Polanco PM, Zenati MS, Hogg ME, et al. (2016) An analysis of risk factors for pancreatic fistula after robotic pancreaticoduodenectomy: outcomes from a consecutive series of standardized pancreatic reconstructions. *Surg Endosc* 30(4):1523–1529.
53. De Pastena M, van Hilst J, de Rooij T, et al. (2018) Laparoscopic Pancreatoduodenectomy With Modified Blumgart Pancreaticojejunostomy. *J Vis Exp* 136:56819.
54. Hirono S, Kawai M, Okada KI, et al. (2019) Modified Blumgart mattress suture versus conventional interrupted suture in pancreaticojejunostomy during pancreaticoduodenectomy: randomized controlled trial. *Ann Surg* 269(2):243–251.
55. Kawakatsu S, Inoue Y, Mise Y, et al (2018) Comparison of pancreateojejunostomy techniques in patients with a soft pancreas: Kakita anastomosis and Blumgart anastomosis. *BMC Surg* 18(1):88.
56. Kojima T, Niguma T, Watanabe N, et al. (2018) Modified Blumgart anastomosis with the “complete packing method” reduces the incidence of pancreatic fistula and complications after resection of the head of the pancreas. *Am J Surg* 216(5):941–948.
57. Winter JM, Cameron JL, Campbell KA, et al. Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. *J Gastrointest Surg* 2006; 10:128.
58. Poon RT, Fan ST, Lo CM, et al. External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. *Ann Surg* 2007; 246:425.
59. Motoi F, Egawa S, Rikiyama T, et al. Randomized clinical trial of external stent drainage of the pancreatic duct to reduce postoperative pancreatic fistula after pancreaticojejunostomy. *Br J Surg* 2012; 99:524.
60. Pessaux P, Sauvanet A, Mariette C, et al. External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial. *Ann Surg* 2011; 253:879.
61. Kuroki T, Tajima Y, Kitasato A, et al. Stenting versus non-stenting in pancreaticojejunostomy: a prospective study limited to a normal pancreas without fibrosis sorted by using dynamic MRI. *Pancreas* 2011; 40:25.
62. Suc B, Msika S, Fingerhut A, et al. Temporary fibrin glue occlusion of the main pancreatic duct in the prevention of intra-abdominal complications after pancreatic resection: prospective randomized trial. *Ann Surg* 2003; 237:57.

63. Lillemoe KD, Cameron JL, Kim MP, et al. Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial. *J Gastrointest Surg* 2004; 8:766.
64. Deng Y, He S, Cheng Y, et al. Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. *Cochrane Database Syst Rev* 2020; 3:CD009621.
65. Ke S, Ding XM, Gao J, et al. A prospective, randomized trial of Roux-en-Y reconstruction with isolated pancreatic drainage versus conventional loop reconstruction after pancreaticoduodenectomy. *Surgery* 2013; 153:743.
66. Busquets J, Martín S, Fabregat J, et al. Randomized trial of two types of gastrojejunostomy after pancreateoduodenectomy and risk of delayed gastric emptying (PAUDA trial). *Br J Surg* 2019; 106:46.
67. Strasberg SM, Drebini JA, Soper NJ. Evolution and current status of the Whipple procedure: an update for gastroenterologists. *Gastroenterology* 1997; 113:983.
68. Tsallis K, Antoniou N, Koukouritaki Z, et al. Successful treatment of recurrent cholangitis by constructing a hepaticojejunostomy with long Roux-en-Y limb in a long-term surviving patient after a Whipple procedure for pancreatic adenocarcinoma. *Am J Case Rep* 2014; 15:348.
69. Spiliotis J, Karnabatidis D, Vaxevanidou A, et al. Acute cholangitis due to afferent loop syndrome after a Whipple procedure: a case report. *Cases J* 2009; 2:6339.
70. Eshuis WJ, van Eijck CH, Gerhards MF, et al. Antecolic versus retrocolic route of the gastroenteric anastomosis after pancreateoduodenectomy: a randomized controlled trial. *Ann Surg* 2014; 259:45.
71. Tamandl D, Sahora K, Prucker J, et al. Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: a prospective randomized study. *World J Surg* 2014; 38:465.
72. Hüttner FJ, Klotz R, Ulrich A, et al. Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy. *Cochrane Database Syst Rev* 2016; 9:CD011862.
73. Jilesen AP, van Eijck CH, Busch OR, et al. Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor. *World J Surg* 2016; 40:715.